IMPACT Therapeutics Inc is a China-based company primarily engaged in the research, development, and commercialization of pharmaceutical products. The Company is principally engaged in the research and development of synthetic lethality-based precision anti-cancer therapies. The Company's product pipeline is primarily composed of Senaparib, as well as novel antibody-drug conjugates (ADCs) and degrader candidates. The Company distributes its products within the domestic market and to overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
04/26/04	HK$8.625	+9.59%	1,68,11,800
03/26/03	HK$7.870	-4.49%	2,10,86,600
02/26/02	HK$8.240	-3.12%	20,91,400
30/26/30	HK$8.505	-11.36%	22,64,992
29/26/29	HK$9.595	-8.44%	27,42,000

Delayed Quote Hong Kong S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

7.339CNY

Average target price

27.28CNY

Spread / Average Target

+271.65%

Consensus

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - IMPACT Therapeutics, Inc

Company calendar

Market Closed - Hong Kong S.E. 01:38:10 04/11/2026 pm IST			5-day change	1st Jan Change
8.625 ^HKD	+9.59%		-17.15%	-

23/10	Impact Therapeutics Presents Results from Three Tumor Drug Studies at European Oncology Meeting	MT
23/10	IMPACT Therapeutics, Inc Presents Latest Clinical Data For Senaparib And PARP1-Selective Inhibitors IMP1734 And IMP1707 At 2026 ESMO Congress	CI

Market Cap	207.31Cr 243.62Cr 31Cr 28Cr 25Cr 23Cr 43Cr 2.93TCr 44Cr 303.28Cr 121.58Cr 1.55TCr 116.55Cr 114.06Cr 4.92TCr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	125.67Cr 147.68Cr 19Cr 17Cr 15Cr 14Cr 26Cr 1.78TCr 27Cr 183.84Cr 74Cr 941.49Cr 71Cr 69Cr 2.98TCr	EV / Sales 2026 *	4.75x	EV / Sales 2027 *	1.7x
Free-Float	53.09%	Yield 2026 *	-	Yield 2027 *	-

23/10	Impact Therapeutics Presents Results from Three Tumor Drug Studies at European Oncology Meeting	MT
23/10	IMPACT Therapeutics, Inc Presents Latest Clinical Data For Senaparib And PARP1-Selective Inhibitors IMP1734 And IMP1707 At 2026 ESMO Congress	CI
18/09	IMPACT Therapeutics And Pharmanovia Receive Positive CHMP Opinion For Senaparib As First-Line Maintenance Treatment Of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, And Primary Peritoneal Cancer	CI
18/09	Impact Therapeutics Gets Positive EMA Opinion for Ovarian Cancer Drug	MT
07/09	Impact Therapeutics Joins Shenzhen-and Shanghai-Hong Kong Stock Connect Programs	MT
03/09	Hong Kong Stocks Fall on Thursday, Amid Bond Selloff, Rate Fears; HUTCHMED Jumps 14%	MT
03/09	Impact Therapeutics CEO Boosts Shareholding	MT
31/08	IMPACT Therapeutics, Inc Reports Earnings Results for the Half Year Ended June 30, 2026	CI
24/08	IMPACT Therapeutics to Join Hang Seng Composite Index	MT
12/08	Impact Therapeutics Announces IMP2794 as A Preclinical Candidate, A Highly Kat6a-Specific PROTAC from Its Proprietary Targeted Protein Degradation Platform	CI
11/08	IMPACT Therapeutics, Inc. Provides Preliminary Consolidated Earnings Guidance for the Six Months Ended 30 June 2026	CI
31/07	IMPACT Therapeutics, Inc and Pharmanovia Enter Exclusive License Agreement For Senaparib In Europe, Middle East And North Africa, Australia And New Zealand	CI
28/07	IMPACT Therapeutics, Inc Announces IMP3201 As A Preclinical Candidate, A First-In-Class CEACAM5-Targeted Dual-Payload ADC	CI

1 day	+9.59%
1 week	-17.15%
Current month	+1.41%
1 month	-39.30%
3 months	-25.65%

IMPACT Therapeutics, Inc Share Price

Stocks

7630

CNE100007LG4

Biotechnology & Medical Research

Valuation: IMPACT Therapeutics, Inc

Chart: IMPACT Therapeutics, Inc

Latest news: IMPACT Therapeutics, Inc

Press Releases: IMPACT Therapeutics, Inc

Quotes and Performance

Price Extremes

Managers and Directors: IMPACT Therapeutics, Inc

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

1 week	7.74	10.59
1 month	7.74	14.76
Current year	7.74	47.98
1 year	7.74	47.98
3 years	7.74	47.98
5 years	7.74	47.98
10 years	7.74	47.98

Manager	Title	Age	Since
Sui Xiong Cai CEO	Chief Executive Officer	69	01/06/2014
Hui Jun Deng DFI	Director of Finance/CFO	51	01/05/2024
Yan Hua Xu CTO	Chief Tech/Sci/R&D Officer	44	01/01/2025

Director	Title	Age	Since
Ye Tian BRD	Director/Board Member	69	01/06/2014
Sui Xiong Cai BRD	Director/Board Member	69	01/06/2014
Ning Ma BRD	Director/Board Member	44	01/03/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMPACT THERAPEUTICS, INC	+9.59%	-17.15%	-	-	28Cr
WUXI APPTEC CO., LTD.	+10.00%	+5.18%	+54.35%	+71.20%	6.06TCr
LONZA GROUP AG	+1.44%	+4.06%	+22.70%	+101.03%	5.55TCr
ARGENX SE	+3.32%	+4.11%	+14.82%	+75.04%	5.52TCr
IQVIA HOLDINGS INC.	+0.46%	-2.86%	+23.34%	+33.77%	4.33TCr
BEONE MEDICINES AG	+6.42%	+3.20%	+21.14%	+105.56%	4.04TCr
REVOLUTION MEDICINES, INC.	+2.82%	+7.24%	+236.59%	+801.17%	4.16TCr
GENMAB A/S	-3.79%	+19.39%	+91.90%	+77.13%	3.33TCr
CELLTRION, INC.	+5.32%	+6.04%	+20.27%	+52.98%	3.23TCr
INSMED INCORPORATED	+5.32%	+15.84%	-40.93%	+342.66%	2.29TCr
Average	+4.09%	+2.08%	+49.35%	+184.51%	3.85TCr
Weighted average by Cap.	+3.73%	+4.04%	+51.58%	+169.51%

	2026 *	2027 *
Net sales	26Cr 31Cr 3.97Cr 3.53Cr 3.24Cr 2.95Cr 5.54Cr 374.81Cr 5.66Cr 39Cr 16Cr 198.38Cr 15Cr 15Cr 628.43Cr	63Cr 74Cr 9.43Cr 8.4Cr 7.71Cr 7Cr 13Cr 891.26Cr 13Cr 92Cr 37Cr 471.72Cr 35Cr 35Cr 1.49TCr
Net income	-	-
Net Debt	-82Cr -96Cr -12Cr -11Cr -9.99Cr -9.08Cr -17Cr -1.16TCr -17Cr -119.44Cr -48Cr -611.67Cr -46Cr -45Cr -1.94TCr	-100.57Cr -118.19Cr -15Cr -13Cr -12Cr -11Cr -21Cr -1.42TCr -22Cr -147.13Cr -59Cr -753.5Cr -57Cr -55Cr -2.39TCr